

# 2nd Quarter 2020 Preferred Drug List Update

## UnitedHealthcare Community Plan of California

UnitedHealthcare Community Plan's Preferred Drug List (PDL) is updated quarterly by our Pharmacy and Therapeutics Committee. Please review the changes and update your references as necessary.

You may also view the changes at [UHCprovider.com/plans](http://UHCprovider.com/plans) > Choose Your State > Medicaid (Community Plan) > Pharmacy Resources and Physician Administered Drugs.

We provided a list of available alternatives to UnitedHealthcare Community Plan members whose current treatment includes a medication removed from the PDL. Please provide affected members a prescription for a preferred alternative in one of the following ways:

- Call or fax the pharmacy.
- Use e-Script.
- Write a new prescription and give it directly to the member.

If a preferred alternative is not appropriate, please call **800-310-6826** for prior authorization for the UnitedHealthcare Community Plan member to remain on their current medication.

### Changes will be effective April 1, 2020

#### PDL Additions

Brand Name	Generic Name	Comments
Adderall XR®*	Amphetamine/ dextroamphetamine extended-release capsule	Indicated for the treatment of attention deficit hyperactivity disorder (ADHD). Diagnosis required. Change effective February 1, 2020.
Baqsimi™	Glucagon nasal powder	Indicated for the treatment of severe hypoglycemia in patients with diabetes. Change effective February 1, 2020.
Fasenra®	Benralizumab injection	Indicated for the add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Prior authorization required. Available through specialty pharmacy.
Glucagon Emergency Kit for Low Blood Sugar (manufactured by Fresenius)	Glucagon solution for injection	Indicated for the treatment of severe hypoglycemia in patients with diabetes. Change effective February 1, 2020.
Gvoke™	Glucagon auto-injector and prefilled syringe	Indicated for the treatment of severe hypoglycemia in patients with diabetes. Change effective February 1, 2020.
Ilumya™	Tildrakizumab-asmn injection	Indicated for the treatment of moderate to severe plaque psoriasis. Prior authorization required. Available through specialty pharmacy.
Nubeqa™	Darolutamide tablet	Indicated for the treatment of non-metastatic castration resistant prostate cancer. Prior authorization required. Available through specialty pharmacy.
Nucala®	Mepolizumab injection	Indicated for the treatment eosinophilic granulomatosis with polyangiitis and for the add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Prior authorization required.

		Available through specialty pharmacy.
Rozlytrek™	Entrectinib capsule	Indicated for the treatment of ROS1-positive non-small cell lung cancer and solid tumors with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. Prior authorization required. Available through specialty pharmacy.
Turalio™	Pexidartinib capsule	Indicated for the treatment of tenosynovial giant cell tumor. Prior authorization required. Available through specialty pharmacy.

\* Only generics are preferred

#### PDL Modifications

Brand Name	Generic Name	Comments
Xeljanz®/Xeljanz® XR	Tofacitinib tablet and extended-release tablet	Current rheumatoid arthritis utilizers will be required to transition to Olumiant unless the prescriber attests that member is stable on therapy and should not be switched.

#### Removed from PDL

Brand Name	Generic Name	Comments
Adderall XR™	Amphetamine/dextroamphetamine extended-release capsule	Amphetamine/dextroamphetamine extended-release capsule (generic Adderall XR™) is an alternate option. Current utilizers will be required to transition to amphetamine/dextroamphetamine extended-release capsule (generic Adderall XR™). Change will be effective August 1, 2020.
Alphagan® P 0.1%	Brimonidine ophthalmic solution	Brimonidine 0.15% and 0.2% ophthalmic solution are alternate options. Current utilizers will not be grandfathered.
Betimol®	Timolol ophthalmic solution	Timolol maleate ophthalmic solution is an alternate option. Current utilizers will not be grandfathered.
Blephamide®	Sulfacetamide sodium and prednisolone ophthalmic suspension	Neomycin/polymyxin B/dexamethasone ophthalmic solution and ointment are alternate options. Current utilizers will not be grandfathered.
Blephamide® SOP	Sulfacetamide sodium and prednisolone ophthalmic ointment	Neomycin/polymyxin B/dexamethasone ophthalmic solution and ointment are alternate options. Current utilizers will not be grandfathered.
Ciloxan®	Ciprofloxacin ophthalmic ointment	Ciprofloxacin ophthalmic solution is an alternate option. Current utilizers will not be grandfathered.
N/A	Neomycin/polymyxin B/hydrocortisone ophthalmic suspension	Neomycin/polymyxin B/dexamethasone ophthalmic solution and ointment are alternate options. Current utilizers will not be grandfathered.
Pred-G®	Gentamicin/prednisolone ophthalmic suspension	Pred-G® SOP ophthalmic ointment and tobramycin/dexamethasone ophthalmic suspension are alternate options. Current utilizers will not be grandfathered.
Prenatal Vitamins	N/A	CitraNatal® Pak DHA tablet, CitraNatal® Rx tablet, CompleteNate chewable tablet, Nestabs® tablet, SE-Natal 19 tablet and chewable tablet, Select-OB® caplet, Thrivite 19 tablet, and Vitafol®-OB tablet will be removed from the PDL. Various other prenatal vitamins will be available. Current utilizers will be grandfathered for one year.
Timoptic® Ocupose®	Timolol maleate preservative free	Timolol maleate ophthalmic solution is an alternate option. Current utilizers will not be grandfathered.

	ophthalmic solution	
Timoptic-XE®	Timolol maleate ophthalmic gel forming solution	Timolol maleate ophthalmic solution is an alternate option. Current utilizers will not be grandfathered.
TobraDex®	Tobramycin/dexamethasone ophthalmic ointment	Pred-G® SOP ophthalmic ointment and tobramycin/dexamethasone ophthalmic suspension are alternate options. Current utilizers will not be grandfathered.
Tobrex®	Tobramycin ophthalmic ointment	Tobramycin ophthalmic solution is an alternate option. Current utilizers will not be grandfathered.

## Contact Us

If you have any questions, please call UnitedHealthcare Community Plan's Pharmacy Department at 800-310-6826. Thank you.